SEC Filing Summary: Cerecor Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. on March 18, 2019. The filing serves to announce the company's financial results for the three and twelve months ended December 31, 2018. The registrant is identified as an Emerging Growth Company. Note: The input metadata referenced "Avalo Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Cerecor Inc.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing does not explicitly list material changes versus prior periods within the body text. It directs readers to the attached press release for the full announcement of results for the periods ended December 31, 2018.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to the liabilities of that section, except as expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in Exhibit 99.1 (Press Release dated March 18, 2019).
- Confirm the company name discrepancy between the request metadata (Avalo Therapeutics) and the filing text (Cerecor Inc.).
- Review the full press release for any forward-looking statements or operational updates not captured in this summary.
- Check for subsequent filings that may update the financial condition as of the filing date.